These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34129738)

  • 1. Pharmacogenetics-Guided Advances in Antipsychotic Treatment.
    Islam F; Men X; Yoshida K; Zai CC; Müller DJ
    Clin Pharmacol Ther; 2021 Sep; 110(3):582-588. PubMed ID: 34129738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New findings in pharmacogenetics of schizophrenia.
    Zai CC; Tiwari AK; Zai GC; Maes MS; Kennedy JL
    Curr Opin Psychiatry; 2018 May; 31(3):200-212. PubMed ID: 29528898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.
    Teng Y; Sandhu A; Liemburg EJ; Naderi E; Alizadeh BZ
    J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.
    Thelma B; Srivastava V; Tiwari AK
    Pharmacogenomics; 2008 Sep; 9(9):1285-306. PubMed ID: 18781856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
    de Leon J; Susce MT; Pan RM; Koch WH; Wedlund PJ
    J Clin Psychopharmacol; 2005 Oct; 25(5):448-56. PubMed ID: 16160620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
    Lanning RK; Zai CC; Müller DJ
    Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.
    Jameson A; Faisal M; Fylan B; Bristow GC; Sohal J; Dalton C; Sagoo GS; Cardno AG; McLean SL
    J Psychopharmacol; 2024 Apr; 38(4):382-394. PubMed ID: 38494658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
    Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
    Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of psychotropic drug response.
    Malhotra AK; Murphy GM; Kennedy JL
    Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver enzyme
    Lu JY; Tiwari AK; Freeman N; Zai GC; Luca V; Müller DJ; Tampakeras M; Herbert D; Emmerson H; Cheema SY; King N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC
    Pharmacogenomics; 2020 Oct; 21(15):1065-1072. PubMed ID: 32969762
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacogenetics of antipsychotic-induced adverse events.
    Müller DJ; Chowdhury NI; Zai CC
    Curr Opin Psychiatry; 2013 Mar; 26(2):144-50. PubMed ID: 23370274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis.
    Gressier F; Porcelli S; Calati R; Serretti A
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):163-185. PubMed ID: 26792444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics.
    Maier W; Zobel A
    Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():12-20. PubMed ID: 18344045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.
    Goldstein JI; Jarskog LF; Hilliard C; Alfirevic A; Duncan L; Fourches D; Huang H; Lek M; Neale BM; Ripke S; Shianna K; Szatkiewicz JP; Tropsha A; van den Oord EJ; Cascorbi I; Dettling M; Gazit E; Goff DC; Holden AL; Kelly DL; Malhotra AK; Nielsen J; Pirmohamed M; Rujescu D; Werge T; Levy DL; Josiassen RC; Kennedy JL; Lieberman JA; Daly MJ; Sullivan PF
    Nat Commun; 2014 Sep; 5():4757. PubMed ID: 25187353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.
    Yoshida K; Müller DJ
    Mol Neuropsychiatry; 2020 Apr; 5(Suppl 1):1-26. PubMed ID: 32399466
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Maruf AA; Stein K; Arnold PD; Aitchison KJ; Müller DJ; Bousman C
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):33-45. PubMed ID: 33074724
    [No Abstract]   [Full Text] [Related]  

  • 19. Applications of pharmacogenetics in psychiatry: personalisation of treatment.
    Arranz MJ; Munro J; Osborne S; Collier D; Kerwin RW
    Expert Opin Pharmacother; 2001 Apr; 2(4):537-42. PubMed ID: 11336604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics in psychiatry: implications for practice.
    Moore TR; Hill AM; Panguluri SK
    Recent Pat Biotechnol; 2014; 8(2):152-9. PubMed ID: 25185985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.